Solara Active Pharma Sciences has said it has come to know that US-based Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules USP (150-mg and 300-mg strengths) due to detected trace amounts of impurity N nitrosodimethylamine. Mylan also indicated that the recall is voluntary and it has not received any reports of adverse events related to these batches to date. Solara Active is in the process of collecting corresponding lots of API from Mylan to carry out its internal investigation. The overall sales of this API to the US market comprise less than 0.1 per cent of total revenues, it further said. Shares of Solara Active closed 0.50 per cent higher at ₹422.65 on the BSE.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.